Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Eliapixant in Healthy Japanese Men
NCT04265781Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of eliapixant in endometriosis, overactive bladder (OAB), diabetic neuropathy and 1 more (4 arms), sponsored by Bayer. Primary endpoint: Frequency and Severity of Treatment-Emergent Adverse Events up to 27 days. Started Feb 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
endometriosisoveractive bladder (OAB)diabetic neuropathychronic cough
Beyond the preview
Go deeper on NCT04265781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265781.